Literature DB >> 7678998

Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis.

E M Conway1, B Nowakowski.   

Abstract

Thrombomodulin (TM) is a transmembrane glycoprotein that interacts with thrombin, thereby serving as a cofactor in the activation of protein C, a major physiologically relevant natural anticoagulant. Although initially described as a vascular endothelial cell receptor, TM has also been reported to be synthesized by several cells, including megakaryocytes, platelets, monocytes, neutrophils (PMN), mesothelial cells, and synovial lining cells. A prominent feature of rheumatoid arthritis (RA) is infiltration of PMN into the joint space. To determine whether TM might play a role in the inflammatory process, we examined synovial fluid for the presence of TM in 10 patients with RA and five patients with osteoarthritis (OA). We determined that the mean synovial fluid and plasma TM levels in the OA group were 23.5 ng/mL and 24.2 ng/mL, respectively, whereas those with RA had a significantly elevated mean synovial fluid TM level of 136.2 ng/mL as compared with the plasma TM concentration of 43.9 ng/mL (P < .05). Synovial fluid TM levels did not correlate with PMN counts (r = .261). Purified TM from synovial fluid was identical in molecular weight to plasma-derived TM and was biologically functional with respect to protein C cofactor activity. Using direct immunofluorescence, we determined that adherent cultured synovial fluid cells that are not monocytoid in origin express surface and cytoplasmic TM, thereby providing an alternative source of the protein. Biologic activity of the cell-surface TM was confirmed by acceleration of thrombin-dependent protein C activation. Northern analysis of RNA extracted from the cultured cells indicated that TM messenger RNA was present, suggesting local synthesis. Our results indicate that in RA-associated synovial effusions, biologically active TM is increased, the source of which may be from plasma, PMN, and/or synovial lining cells. TM may play a regulatory role either in fibrin deposition in the inflamed joint and/or in the progression of the inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678998

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Thrombin in inflammation and healing: relevance to rheumatoid arthritis.

Authors:  R Morris; P G Winyard; D R Blake; C J Morris
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

Review 2.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

Review 3.  Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.

Authors:  Mallorie Boron; Tiffany Hauzer-Martin; Joseph Keil; Xue-Long Sun
Journal:  TH Open       Date:  2022-07-11

4.  Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis.

Authors:  Shadi A Sharif; Xiaoyan Du; Timothy Myles; Jason J Song; Elizabeth Price; David M Lee; Stuart B Goodman; Mariko Nagashima; John Morser; William H Robinson; Lawrence L K Leung
Journal:  Arthritis Rheum       Date:  2009-10

Review 5.  The role of thrombomodulin lectin-like domain in inflammation.

Authors:  Yi-Heng Li; Cheng-Hsiang Kuo; Guey-Yueh Shi; Hua-Lin Wu
Journal:  J Biomed Sci       Date:  2012-03-27       Impact factor: 8.410

6.  Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.

Authors:  Tine Wyseure; Esther J Cooke; Paul J Declerck; Niels Behrendt; Joost C M Meijers; Annette von Drygalski; Laurent O Mosnier
Journal:  Blood       Date:  2018-07-19       Impact factor: 25.476

Review 7.  C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.

Authors:  Kabir A Khan; Jack L McMurray; Fiyaz Mohammed; Roy Bicknell
Journal:  FEBS J       Date:  2019-07-29       Impact factor: 5.542

Review 8.  Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects.

Authors:  Fiona A Martin; Ronan P Murphy; Philip M Cummins
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-19       Impact factor: 4.733

9.  Protective Effects of Recombinant Human Soluble Thrombomodulin on Lipopolysaccharide-Induced Acute Kidney Injury.

Authors:  Yuji Nozaki; Jinhai Ri; Kenji Sakai; Kaoru Niki; Masanori Funauchi; Itaru Matsumura
Journal:  Int J Mol Sci       Date:  2020-04-05       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.